VEKTIS Study Results: Primary Endpoint

  • Primary efficacy endpoint (superiority of CsA CE vs. vehicle over 4 months) was met
  • Differences in LS means vs. vehicle were significant for both the high-dose (0.76; 95% CI, 0.26–1.27; p=0.007) and low-dose groups (0.67; 95% CI, 0.16–1.18; p=0.010)

CI, confidence interval; LS, least-squares; SEM, standard error of the mean.
Bremond-Gignac D et al. Presented at the 2017 Annual Meeting of the American Academy of Ophthalmology; Nov. 11–14, 2017; New Orleans, Louisiana.

VEKTIS Study: CFS Improvement During 8-Month Follow-up

  • 8-month follow-up efficacy analyses demonstrated stability of improvements in CFS scores achieved during the 4-month randomized period, especially among patients who continued treatment beyond Month 4

SEM, standard error of the mean.
Leonardi A et al. Presented at the 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 7–11, 2017; Baltimore, Maryland.

VEKTIS Study: Evolution of VKC Symptoms

  • Photophobia
  • Mucous Discharge
  • Tearing
  • Itching

*p <0.05 vs vehicle; **p <0.001 vs vehicle.
Leonardi A et al. Presented at 8th EU Cornea Congress; October 6–7, 2017; Lisbon, Portugal.

VEKTIS Study: Comparison of Changes From Baseline in QUICK Questionnaire Scores (Active vs. Vehicle)

  • Symptoms Domain
  • Daily Activities Domain

LS, least square.
P-values represent least-squares mean differences vs. vehicle.
Bremond-Gignac D et al. Presented at the 2017 Annual Meeting of the American Academy of Ophthalmology; Nov. 11–14, 2017; New Orleans, Louisiana.

Next